Soleno Therapeutics, Inc.
SLNO
$66.56
$0.911.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 436.92% | 563.11% | 685.26% | 519.08% | 149.32% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 219.70% | 281.03% | 376.93% | 332.00% | 137.87% |
| Operating Income | -172.03% | -281.03% | -376.93% | -332.00% | -137.87% |
| Income Before Tax | -176.84% | -280.98% | -351.04% | -295.33% | -129.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -176.84% | -280.98% | -351.04% | -295.33% | -129.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -176.84% | -280.98% | -351.04% | -295.33% | -129.92% |
| EBIT | -172.03% | -281.03% | -376.93% | -332.00% | -137.87% |
| EBITDA | -177.03% | -291.60% | -396.95% | -353.54% | -147.92% |
| EPS Basic | -70.28% | -72.18% | -43.20% | -2.66% | 16.91% |
| Normalized Basic EPS | -78.34% | -77.89% | -49.62% | -2.14% | 22.54% |
| EPS Diluted | -70.28% | -72.18% | -43.20% | -2.66% | 16.91% |
| Normalized Diluted EPS | -78.34% | -77.89% | -49.62% | -2.14% | 22.54% |
| Average Basic Shares Outstanding | 51.15% | 84.43% | 144.33% | 270.96% | 211.70% |
| Average Diluted Shares Outstanding | 51.15% | 84.43% | 144.33% | 270.96% | 211.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |